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Nonsteroidal Antiinflammatory Drugs and Susceptibility to 
COVID- 19
Joht Singh Chandan,1  Dawit Tefra Zemedikun,2 Rasiah Thayakaran,2 Nathan Byne,3 Samir Dhalla,3 
Dionisio Acosta- Mena,3 Krishna M. Gokhale,2 Tom Thomas,4  Christopher Sainsbury,2 
Anuradhaa Subramanian,2 Jennifer Cooper,2 Astha Anand,2 Kelvin O. Okoth,2 Jingya Wang,2 Nicola J. Adderley,2 
Thomas Taverner,2 Alastair K. Denniston,5 Janet Lord,6 G. Neil Thomas,2 Christopher D. Buckley,7 Karim Raza,8 
Neeraj Bhala,9 Krishnarajah Nirantharakumar,10 and Shamil Haroon2
Objective. To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility 
to developing suspected or confirmed coronavirus disease 2019 (COVID- 19) compared to the use of other common 
analgesics.
Methods. We performed a propensity score– matched cohort study with active comparators, using a large UK 
primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed 
up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to 
those prescribed either co- codamol (paracetamol and codeine) or co- dydramol (paracetamol and dihydrocodeine). A 
total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator 
drugs. The primary outcome measure was the documentation of suspected or confirmed COVID- 19, and the 
secondary outcome measure was all- cause mortality.
Results. During follow- up, the incidence rates of suspected/confirmed COVID- 19 were 15.4 and 19.9 per 1,000 
person- years in the NSAID- exposed group and comparator group, respectively. Adjusted hazard ratios for suspected 
or confirmed COVID-19 among the unmatched and propensity score–matched OA cohorts, using data from clinical 
consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62– 1.10) and 0.79 (95% CI 
0.57– 1.11), respectively, and adjusted hazard ratios for the risk of all-cause mortality were 0.97 (95% CI 0.75– 1.27) 
and 0.85 (95% CI 0.61– 1.20), respectively. There was no effect modification by age or sex.
Conclusion. No increase in the risk of suspected or confirmed COVID- 19 or mortality was observed among 
patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received 
comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be 
safely prescribed during the ongoing pandemic.
INTRODUCTION
The coronavirus disease 2019 (COVID- 19) pandemic, caused 
by severe acute respiratory syndrome coronavirus 2 (SARS– 
CoV- 2), was originally declared a public health emergency on 
January 30, 2020 (1). Since then, the disease has led to the deaths 
of >700,000 individuals globally (2). Nonsteroidal antiinflammatory 
drugs (NSAIDs) are widely used to help control pain in chronic 
diseases such as osteoarthritis (OA) and are often used in groups 
at high risk for COVID- 19, including older populations. However, 
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concerns have been raised regarding the use of NSAIDs in the 
treatment of SARS– CoV- 2 infection, particularly after the French 
Health Minister suggested in March 2020 that NSAIDs might 
aggravate the infection. Pre- pandemic evidence has also sug-
gested a potential association between the use of NSAIDs and 
prolonged or complicated courses of respiratory infection (3– 7).
Furthermore, biologic data raise the possibility of increased risk 
for COVID- 19. Entry of SARS– CoV- 2 into host cells is dependent 
on its receptor, angiotensin- converting enzyme 2 (ACE2) (8), as well 
as priming of the S protein by transmembrane protease serine 2 
(9). Single- cell RNA sequencing has demonstrated ACE2 messen-
ger RNA expression across multiple epithelial cell types through-
out the human body, most notably in the nasal epithelium (10). It 
has been speculated that ibuprofen, one of the most commonly 
used NSAIDs, could up- regulate ACE2 expression and thereby 
increase susceptibility to SARS– CoV- 2 (11). A single study has pre-
viously demonstrated ACE2 up- regulation in the cardiac tissue in 
response to ibuprofen in a rat model of diabetes (12). It is unknown 
if these results would translate to the specific cell types of interest in 
humans and thereby promote susceptibility to SARS– CoV- 2.
Despite these concerns, NSAIDs have remained an impor-
tant therapeutic approach to the management of pain, includ-
ing among older patients (13). However, data on the effects of 
NSAIDs on susceptibility to SARS– CoV- 2 remain sparse, espe-
cially in older cohorts. Both the National Health Service in Eng-
land and the World Health Organization have conducted rapid 
reviews to examine the association between the use of NSAIDs 
and susceptibility to and severity of COVID- 19 (14,15). In both 
reviews it was concluded that there was no clear association 
between NSAIDs and these outcomes but they noted that the 
evidence was scarce. Several studies examined the impact 
of NSAIDs on the disease course in patients with COVID- 19 
(16,17), including those with acute respiratory distress syn-
drome (18). However, smaller- scale clinical studies to date have 
been unable to adequately investigate whether use of NSAIDs 
could confer susceptibility to infection due to SARS– CoV- 2. 
Challenges in the design of studies attempting to address this 
concern include selection bias, as well as an inability to account 
for confounding by indication bias.
To address this question, we conducted a retrospective 
cohort study exploring the association between NSAID use and 
the subsequent development of COVID- 19, using real- world data 
from primary care (6).
PATIENTS AND METHODS
Study design. This was a population- based retrospective 
propensity score– matched cohort study of patients with OA, 
comparing the risk of suspected or confirmed COVID- 19 infection 
among patients prescribed an NSAID (excluding topical prepara-
tions) to those prescribed either co- codamol or co- dydramol as 
active comparators.
Data source. This cohort study used patient data derived 
from The Health Improvement Network (THIN) database. The 
steps involved in data extraction were facilitated by the Data 
Extraction for Epidemiological Research tool (19). THIN is a col-
lection of routinely collected primary care data from UK general 
practices, which use Vision electronic medical records software 
(20). In 2020, THIN included data on ~2.1 million active patients 
from 357 practices. The database is representative of the UK pop-
ulation in terms of demographic structure and prevalence of key 
comorbidities (21).
THIN has been used on numerous occasions in pharmacoep-
idemiologic studies to examine health outcomes and mortality risk 
in patients with OA or to assess drug safety during the COVID- 19 
pandemic (22– 27). Symptoms, examinations, and diagnoses in 
THIN are recorded using a hierarchical clinical coding system 
called Read codes (28). Prescriptions are recorded based on the 
Dictionary of Medicines and Devices and Anatomical Therapeu-
tic Classification systems (29,30). In order to reduce the under-
recording of events, general practices were included 12 months 
following their installment of electronic practice records or from 
the practice’s acceptable mortality recording date (31).
Study population. Adults age ≥18 years with a diagnosis 
of OA who had been registered with an eligible general practice 
for at least 1 year on or before January 30, 2020 (index date) were 
included. Patients with OA were specifically selected because 
they commonly take NSAIDs and other analgesics for chronic 
pain management, and selecting a specific population group 
helps to limit confounding by indication bias from other chronic 
pain conditions that may have differential risks for COVID- 19. 
Patients with a record of rheumatoid arthritis, systemic lupus ery-
thematosus, juvenile arthritis, enteropathic arthritis, reactive arthri-
tis, scleroderma, or ankylosing spondylitis were thus excluded. 
In addition, patients with a history of gastrointestinal bleeding, 
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peptic ulcers, or allergy or adverse reactions to NSAIDs were also 
excluded.
Definition of exposed group and comparator group. 
Current users of NSAIDs or comparator drugs (co- codamol/co- 
dydramol) were defined as patients with prescriptions that lasted 
beyond the index date or those with prescriptions that lasted until 
90 days preceding the index date and with evidence of further 
prescription during the pandemic period. NSAIDs included those 
in chapter 10.1.1 in the British National Formulary, such as ibu-
profen, naproxen, and diclofenac, but excluded aspirin 300 mg 
due to a difference in the biologic mechanism of action (32). The 
complete list of NSAIDs included in the study is shown in Sup-
plementary Table 1 (available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41593/ 
abstract).
Patients with OA with a current prescription for an NSAID 
(exposed group) were compared to patients with a current pre-
scription for co- codamol or co- dydramol (comparator group). 
The 2 groups were mutually exclusive; patients with a current 
prescription for both medications were excluded from the study. 
Co- codamol and co- dydramol are analgesics that are alterna-
tive treatment options for the management of pain in patients 
with OA and have not been implicated in increasing suscepti-
bility to COVID- 19. While there is some evidence that opiates 
have immunosuppressive properties and may increase the risk 
of community- acquired pneumonia, this is only clinically evident 
in patients who are receiving doses of opiates above the equiv-
alent of 20 mg of morphine daily (33). This is greater than the 
dose of opiates that patients in our active comparator cohort 
would be exposed to from taking co- codamol or co- dydramol.
Matching. Using data from the index date, participants in 
the exposed group were propensity score matched to participants 
in the comparator group. Propensity scores for the use of NSAIDs 
were estimated using a logistic regression model including a set 
of covariates as described below. To ensure positivity (having 
adequate variation in the treatment of interest within confounder 
strata), propensity scores were truncated and only participants 
with propensity scores that fell within the common support region 
using a caliper width of 0.2 were eligible for matching. Participants 
in the exposed group were then matched 1:1 to patients taking 
comparator drugs, by propensity score using the nearest neigh-
bor algorithm.
Follow- up period. Patients were followed up from January 
30, 2020 (index date) until the earliest of the following dates: date 
of the outcome, date of death, date patient left practice/data set, 
date practice ceased contributing to the database, or study end 
date (July 31, 2020). The latest available covariate data recorded 
on or before the index date were used to calculate propensity 
scores and to adjust for covariates in the analysis.
Outcome measures. The primary outcome measure 
was a composite of confirmed or clinician- suspected diag-
noses of COVID- 19. The secondary outcome measure was 
the risk of all- cause mortality and was limited to confirmed 
 COVID- 19 cases in a sensitivity analysis. The outcome meas-
ures were defined using the relevant clinical Read codes listed 
in Supplementary Table 2 (available on the Arthritis & Rheuma-
tology website at http://onlin e libr ary.wiley.com/doi/10.1002/
art.41593/ abstract).
Covariates. The latest available covariate data recorded 
prior to the index date were obtained and used for propen-
sity score matching and adjustment in the outcome model. 
The list of covariates included currently known risk factors 
for the development of COVID- 19 (34). These included 1) 
sociodemographic characteristics (age and sex); 2) lifestyle 
and metabolic profile mea sures (smoking status, body mass 
index [BMI], systolic and diastolic blood pressure, and esti-
mated glomerular filtration rate); and 3) presence of comorbid 
conditions such as type 2 diabetes mellitus, cardiovascular 
Figure 1. Flow chart showing disposition of the osteoarthritis patients 
in each group. MSK = mus culoskeletal; NSAIDs = nonsteroidal anti-
inflammatory drugs; GI = gastrointestinal.
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disease (peripheral vascular disease, stroke, ischemic 
heart disease, and heart failure), atrial fibrillation, asthma, 
chronic obstructive pulmonary disease, cancer, liver disease 
(mild, moderate, and severe), psoriasis, neurologic disorders 
(Parkinson’s disease, motor neuron disease, multiple scle-
rosis, myasthenia gravis, and epilepsy), dementia, vitamin D 
deficiency, solid organ transplant, and use of immunosup-
pressive drug therapies.
Smoking status was categorized as nonsmoker, ex- 
smoker, or current smoker. BMI was categorized as <25 kg/m2 
(normal/underweight), 25– 30 kg/m2 (overweight), >30– 35 kg/m2 
(obese), or >35 kg/m2 (severely obese). Physiologic and labora-
tory mea sures were categorized into appropriate clinically mean-
ingful groups. All covariates listed above were included in the 
propensity score matching process and for adjustment in the 
analysis.
Table 1. Baseline characteristics of the study population*
Unmatched cohort Matched cohort
NSAID
(n = 13,202)
Comparator
(n = 12,457)
NSAID
(n = 8,595)
Comparator
(n = 8,595)
Male sex, no. (%) 4,992 (37.8) 4,156 (33.4) 2,990 (34.8) 2,938 (34.2)
Age, years 65.35 ± 10.7 71.71 ± 11.3 68.39 ± 10.4 68.08 ± 10.5
Age categories, no. (%)
<40 years 123 (0.9) 69 (0.6) 48 (0.6) 66 (0.8)
40– 49 years 727 (5.5) 308 (2.5) 283 (3.3) 297 (3.5)
50– 59 years 3,097 (23.5) 1,420 (11.4) 1,372 (16.0) 1,380 (16.1)
60– 69 years 4,539 (34.4) 3,177 (25.5) 2,825 (32.9) 2,810 (32.7)
70– 79 years 3,484 (26.4) 4,219 (33.9) 2,867 (33.4) 2,859 (33.3)
≥80 years 1,232 (9.3) 3,264 (26.2) 1,200 (14.0) 1,183 (13.8)
Smoking status, no. (%)
Nonsmoker 6,995 (53.0) 5,966 (47.9) 4,294 (50.0) 4,335 (50.4)
Ex- smoker 4,285 (32.5) 4,653 (37.4) 3,004 (35.0) 2,962 (34.5)
Smoker 1,824 (13.8) 1,798 (14.4) 1,259 (14.7) 1,271 (14.8)
Missing data 98 (0.7) 40 (0.3) 38 (0.4) 27 (0.3)
BMI, kg/m2 31.03 ± 6.9 30.77 ± 7.0 30.86 ± 6.9 31.09 ± 7.1
BMI categories, no. (%)
Normal/underweight (<25) 2,290 (17.4) 2,352 (18.9) 1,535 (17.9) 1,523 (17.7)
Overweight (25– 30) 4,152 (31.5) 3,906 (31.4) 2,726 (31.7) 2,703 (31.5)
Obese (>30) 6,287 (47.6) 5,908 (47.4) 4,105 (47.8) 4,144 (48.2)
Missing data 473 (3.6) 291 (2.3) 229 (2.7) 225 (2.6)
Systolic BP, mm Hg 133.6 ± 14.5 133.8 ±14.9 133.9 ± 14.5 134.2 ± 14.5
Diastolic BP, mm Hg 78.43 ± 9.1 76.60 ± 9.5 77.62 ± 9.05 77.88 ± 9.19
eGFR, ml/minute 84.6 ± 18.74 79.9 ± 21.55 83.1 ± 19.4 84.4 ± 19.3
eGFR category, no. (%)
>90 (stage 1) 4,478 (33.9) 3,601 (28.9) 2,797 (32.5) 2,875 (33.5)
60– 90 (stage 2) 7,494 (56.8) 6,761 (54.3) 4,853 (56.5) 4,969 (57.8)
30– 59 (stage 3) 833 (6.3) 1,830 (14.7) 764 (8.9) 598 (7.0)
<30 (stage 4) 13 (0.1) 92 (0.7) 13 (0.2) 2 (0.0)
Missing data 384 (2.9) 173 (1.4) 168 (2.0) 151 (1.8)
Baseline conditions, no. (%)
AF 264 (2.0) 1,309 (10.5) 263 (3.1) 70 (0.8)
CVD 1,221 (9.3) 3,146 (25.3) 1,173 (13.7) 831 (9.7)
Diabetes 1,707 (12.9) 2,816 (22.6) 1,460 (17.0) 1,364 (15.9)
Dementia 114 (0.9) 358 (2.9) 110 (1.3) 63 (0.7)
Vitamin D deficiency 249 (1.9) 375 (3.0) 202 (2.4) 186 (2.2)
Cancer 1,188 (9.0) 1,509 (12.1) 921 (10.7) 895 (10.4)
Liver disease 297 (2.3) 392 (3.2) 242 (2.8) 243 (2.8)
Asthma 2,147 (16.3) 2,488 (20.0) 1,524 (17.7) 1,526 (17.8)
Psoriasis 740 (5.6) 1,506 (12.1) 694 (8.1) 610 (7.1)
COPD 740 (5.6) 1,506 (12.1) 694 (8.1) 610 (7.1)
Neurologic disorders† 144 (1.1) 170 (1.4) 107 (1.2) 112 (1.3)
Solid organ transplant 1 (0.0) 6 (0.1) 1 (0.0) 0 (0)
Immunologic therapies 80 (0.6) 91 (0.7) 60 (0.7) 59 (0.7)
NSAID use 1 year prior to index date 4,108 (31.12) 1,857 (14.91) 2,769 (32.22) 1,575 (18.32)
* Except where indicated otherwise, values are the mean ± SD. NSAID = nonsteroidal antiinflammatory drug; BMI = body 
mass index; BP = blood pressure; eGFR = estimated glomerular filtration rate; AF = atrial fibrillation; CVD = cardiovascular 
disease; COPD = chronic obstructive pulmonary disease. 
† Neurologic disorders: Parkinson’s disease, motor neuron disease, multiple sclerosis, myasthenia gravis, and epilepsy. 
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Missing data. Missing values for smoking status and phys-
iologic/laboratory measures were treated as a separate missing 
category for each variable. The absence of a record of any diag-
nosis was taken to indicate the absence of the condition.
Statistical analysis. Descriptive statistics were used to 
describe the exposed and comparator groups and were described 
for both groups before and after propensity score matching. His-
tograms of propensity scores in the exposed and the compara-
tor groups were generated before and after matching, for a visual 
check of the global balance of propensity scores between the 2 
groups.
Crude incidence rates per 1,000 person- years for the pri-
mary and secondary outcome measures were estimated for the 
exposed and comparator cohorts. A Cox proportional hazards 
regression model was used to determine crude incidence rates 
and adjusted hazard ratios (HRs) for NSAIDs compared to the 
comparator drugs for the outcome measure. Survival curves in 
the exposed and the comparator groups were generated for the 
unmatched and the propensity score– matched cohorts.
Subgroup analysis. Two subgroup analyses were con-
ducted to assess for differential associations between COVID- 19 
and NSAID use by age (<65 years versus ≥65 years) and sex. 
Both older age and male sex have previously been identified 
as risk factors for COVID- 19, and we investigated whether this 
extended to differential effects from NSAID exposure (34).
RESULTS
Study population. We identified 13,202 eligible patients 
with OA with a current prescription for an NSAID and 12,457 
patients with a current prescription for comparator drugs (co- 
codamol or co- dydramol) (Figure 1).
Baseline characteristics. In the unmatched cohort (13,202 
exposed patients compared to 12,457 comparator patients), the 
NSAID cohort was younger (mean age 65.4 versus 71.7 years) and 
had a greater proportion of men (37.8% versus 33.4%) compared 
to the comparator cohort (Table 1). Compared to the comparator 
cohort, the NSAID cohort had similar proportions of current smok-
ers and a similar mean BMI. However, those taking NSAIDs had a 
lower prevalence of comorbidities compared to those taking the 
comparator drugs, including cardiovascular disease, diabetes, 
re spiratory disease, and cancers.
Following 1:1 propensity score matching, 8,595 eligible 
patients prescribed NSAIDs were compared to 8,595 matched 
patients prescribed co- codamol or co- dydramol. After matching, 
the demographic and clinical characteristics of both cohorts were 
very similar (Table 1).
Primary and secondary outcome measures. In the 
unmatched cohort during the follow- up period, 101 individuals in 
the exposed group (current NSAID users only) and 122 in the com-
parator group (current co- codamol or co- dydramol users only) 
Figure 2. Adjusted hazard ratio (aHR) (with 95% confidence interval [95% CI]) for developing suspected/confirmed coronavirus disease 2019 
(COVID- 19) or mortality following medication use in both the exposed group and the comparator group. Color figure can be viewed in the online 
issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41593/abstract.
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were diagnosed as having suspected or confirmed COVID- 19, 
corresponding to crude incidence rates (IRs) of 15.4 and 19.9 
per 1,000 person- years, respectively (Table 2). After adjustment 
for potential confounders, no statistically significant difference in 
the risk of confirmed or suspected COVID- 19 was observed in 
users of NSAIDs compared to users of the comparator drugs 
(adjusted HR 0.82 [95% CI 0.62– 1.10]; Figure 2 and Supplemen-
tary Figure 1, available on the Arthritis & Rheumatology website 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41593/ abstract).
During the follow- up period, 92 patients in the exposed group 
died (IR 14.0 per 1,000 person- years), compared to 213 patients 
in the comparator group (IR 34.6 per 1,000 person- years). How-
ever, following adjustment for confounders, there was no signif-
icant difference in mortality between groups (adjusted HR 0.97 
[95% CI 0.75– 1.27]).
Following propensity score matching, 63 patients in the 
exposed group and 76 patients in the comparator group were 
diagnosed as having suspected or confirmed COVID- 19, corre-
sponding to crude IRs of 14.8 and 17.9 per 1,000 person- years, 
respectively. Similarly, no statistically significant difference in the 
risk of COVID- 19 was observed between the 2 groups following 
adjustment (adjusted HR 0.79 [95% CI 0.57– 1.11]). In addition, 
there was no significant difference in the mortality risk between the 
groups (adjusted HR 0.85 [95% CI 0.61– 1.20]).
Sensitivity analysis. In a sensitivity analysis where out-
comes were restricted to only those presenting as confirmed cases 
of COVID- 19, the results remained similar to the main findings 
(Supplementary Table 3, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41593/ 
abstract). When this exclusion criterion was applied to the cohort, 
there were no statistically significant differences in the risk of devel-
oping suspected/confirmed COVID-19 between the exposed and 
comparator groups in the adjusted unmatched cohort analysis 
(adjusted HR 0.71 [95% CI 0.35– 1.43]) and propensity score– 
matched cohort analysis (adjusted HR 0.69 [95% CI 0.29– 1.61]).
Subgroup analysis. There was no significant difference in 
the risk of suspected/confirmed COVID-19 between male patients 
who were prescribed NSAIDs compared to male patients who 
were prescribed the comparator drugs in either the unmatched 
cohort (adjusted HR 0.77 [95% CI 0.48– 1.26]) or the propensity 
score– matched cohort (adjusted HR 0.72 [95% CI 0.40– 1.28]) 
(Supplementary Table 4, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41593/ 
abstract). The results were similar in female patients, both in the 
unmatched cohort (adjusted HR 0.86 [95% CI 0.60– 1.23]) and in 
the propensity score– matched cohort (adjusted HR 0.83 [95% CI 
0.55– 1.26]).
No significant difference in the risk of all-cause mortality 
was observed between the exposed and comparator groups 
among men in either the unmatched cohort (adjusted HR 0.83 
[95% CI 0.55−1.27]) or the propensity score– matched cohort 
(adjusted HR 0.78 [95% CI 0.47−1.32]). The same was also 
true among women in either the unmatched cohort (adjusted 
HR 1.11 [95% CI 0.78−1.57]) or the propensity score– matched 
cohort (adjusted HR 0.94 [95% CI 0.59−1.48]) (Supplementary 
Table 4).
No statistically significant differences in the primary out-
come measure were found after stratification by age (patients 
age <65 and ≥65 years). Among patients age <65 years, there 
was no significant difference in the risk of developing suspected/
confirmed COVID-19 between those prescribed NSAIDs com-
pared to those prescribed the comparator drugs in either the 
unmatched cohort (adjusted HR 0.97 [95% CI 0.63– 1.49]) or 
the propensity score– matched cohort (adjusted HR 0.93 [95% 
CI 0.57– 1.51]) (Supplementary Table 5, http://onlin elibr ary.wiley.
com/doi/10.1002/art.41593/ abstract). However, in those age 
≥65 years, the adjusted HRs were lower, although not significantly 
so, when comparing the risk of developing suspected/confirmed 
COVID-19 between the NSAID-exposed and comparator groups 
in both the unmatched cohort (adjusted HR 0.73 [95% CI 0.49– 
1.09]) and the propensity score– matched cohort (adjusted HR 
0.67 [95% CI 0.42– 1.08]).
Similarly, among patients age <65 years, there were no 
differences in mortality risk between the NSAID-exposed and 
comparator groups in either the unmatched cohort (adjusted 
HR 1.32 [95% CI 0.56−1.11]) or the propensity score– matched 
cohort (adjusted HR 1.12 [95% CI 0.42– 3.01]). There were 
also no differences in mortality risk between the groups in 
patients age ≥65 years, either in the unmatched cohort (adjusted 
HR 0.95 [95% CI 0.71– 1.26]) or the propensity score– matched 
cohort (adjusted HR 0.82 [95% CI 0.57– 1.19]).
DISCUSSION
To our knowledge, this is the first population- based cohort 
study accounting for confounding by indication bias as well as a 
wide range of other potential confounders to examine the effect 
of NSAIDs on subsequent development of suspected or con-
firmed COVID- 19 or mortality. We found no significant associa-
tion between NSAID use and confirmed or suspected COVID- 19 
or all- cause mortality, when compared to use of co- codamol or 
co- dydramol in a large primary care cohort of patients with OA. 
Additionally, there was no significant difference in the associa-
tion between NSAID use and the risk of suspected or confirmed 
 COVID- 19 or mortality in men compared to women. Reassuringly, 
we also found no significant difference in the association between 
NSAID use and the risk of COVID- 19 or mortality in older patients 
compared to younger patients, although older NSAID users had a 
reduction, though not statistically significant, in risk of COVID- 19 
compared to those prescribed comparator drugs. Overall, the 
data clearly show that the use of NSAIDs in this population was 
not associated with increased risk of infection or mortality.
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SARS– CoV- 2 enters host cells via the ACE2 receptor, and 
NSAIDs may increase expression of this enzyme. Therefore, con-
cerns were raised at the outset of the pandemic about the use of 
NSAIDs and susceptibility to COVID- 19. However, our findings do 
not support this conjecture. Indeed, there are parallels between 
our results and those from previous studies investigating the 
impact of ibuprofen on the severity of COVID- 19 in South Korea 
(16) and Denmark (17). In those studies, NSAIDs conferred no 
additional risk of morbidity or mortality. Interestingly, Lund et al also 
attempted to examine the impact of age and sex on COVID- 19 
severity in patients taking NSAIDs compared to their matched 
controls. They identified no clear differences in outcomes across 
age or sex, although the study may not have been sufficiently 
powered to identify these as potential effect modifiers (17).
Our study supports these findings, demonstrating that there 
is no increased risk of susceptibility to COVID- 19 across age or 
sex in patients taking NSAIDs. This is important because older 
patients are at a substantially higher risk of developing COVID- 19 
and have a poorer prognosis (34). These results are also reassur-
ing given the high prevalence of NSAID use in this age group (35). 
Our findings will need to be confirmed in other cohorts, as we 
restricted our analysis to patients with preexisting OA to reduce 
the risk of confounding by indication and immortal time bias. Fur-
ther research into the impact of NSAIDs on the expression of the 
ACE2 receptor and consequent susceptibility to SARS– CoV- 2 in 
relevant human cell types is also urgently required.
Although not targeted at population- based use, the 
 LIBERATE trial is currently exploring outcomes in patients 
given lipid  ibuprofen versus standard care for acute hypoxemic 
 respiratory failure due to COVID- 19 (18). The findings of this trial 
will help confirm whether NSAIDs could be of benefit in the man-
agement of severe COVID- 19.
Our study had several limitations. This was an observational, 
retrospective cohort study and is therefore prone to the effect of 
unmeasured confounding and confounding by indication bias. 
However, we used a propensity score– matched design to min-
imize the effect of a large number of potential confounders. We 
also attempted to limit confounding by indication bias by the inclu-
sion of a carefully selected population group commonly prescribed 
the drugs of interest. The study also explored potential interactions 
by age and sex. The majority of studies on COVID- 19 are based in 
secondary care settings, and this study is also one of the few that 
has explored susceptibility to COVID- 19 in a primary care setting.
An important limitation of our study relates to data quality, 
as the use of electronic health records for epidemiologic research 
largely relies on the accuracy of documentation by health care 
professionals. While prescription data are adequately recorded in 
primary care, we could not account for NSAIDs purchased with-
out a prescription nor could we verify medication compliance. 
However, we anticipate that a large proportion of patients taking 
NSAIDs for chronic pain associated with OA would receive this by 
prescription. Although we do not have details relating to patterns 
of NSAID prescription prior to study entry, we have been able to 
report the proportion of patients who had at least 1 recorded pre-
scription for NSAIDs in the year preceding the index date (Table 1).
As the data were derived from a primary care setting, we 
did not have data on hospitalization, inpatient management, 
or cause- specific mortality. Additionally, we were unable to 
access data relating to socioeconomic status, an important 
risk factor associated with outcomes of COVID- 19 (34). Our 
study was also limited by the number of outcome events, 
which were insufficient to explore effects of different types or 
doses of NSAIDs (36).
Our findings suggest that prescriptions of NSAIDs (excluding 
topical preparations) in primary care does not increase susceptibil-
ity to COVID- 19 or all- cause mortality, including in older patients. 
These findings are reassuring given the high prevalence of NSAID 
use in at- risk groups. Further research is needed to investigate 
whether the use of NSAIDs is associated with adverse outcomes 
from COVID- 19 in patients with confirmed SARS– CoV- 2 infection 
and whether risks differ by NSAID type and dose.
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